Life Sciences

January 2018

Biotech partnering consultant Linda Pullan, PhD, joins six expert panelists currently in the field of bispecifics to discuss the science and business of bispecifics and related multivalent cancer therapeutics... 

January 2018

In this webinar, Mike Rice of Defined Health discusses recent advances in gene and stem cell therapies with an emphasis on therapeutic potential and the remaining hurdles that must be overcome for...

January 2018

We've brought together three practitioners in the space who are enabling the application of AI in drug discovery and development across the spectrum from startup to large pharma to help elucidate how this technology can...

We've compiled deal data for medtech alliances created during Q1-Q2 of 2017 in order by the number of transactions completed. It offers a high level view by types: M&A, Partnering & Asset sales....

October 2017

There is a lot of noise around artificial intelligence (AI) and how it is or isn’t changing the drug development landscape. One of the key benefits of AI is finding the signal in the noise, and in this webinar, we aimed to...

September 2017

During this discussion, four life science founders provided guidance on how executive teams can partner business and science together to overcome the stumbling blocks along the way and achieve results...

September 2017

GDP is the responsibility of everyone that contributes (i.e. via submission or creation) clinical trial documentation to the TMF. This webinar evaluates regulations that support GDP, best practices on how document...

This infographic offers insight on the strategic oncology alliances made during Q1-Q2 of 2017 by geographic region, development phase and molecule type. Get a high level view of the alliance types by...

With a busy 2017, we've compiled the biopharma partnering and M&A deal activity so far this year (through May). Quickly see what collaborations have been forged in 2017 in the various therapeutic areas...

This webinar presents an introduction to the key concepts and methodologies commonly used to evaluate life sciences businesses and assets. Get an explanation of three fundamental concepts in...

 

This white paper discusses the role of non-immuno-oncology treatments for cancer in a world where immuno-oncology is playing a greater role...

This white paper is a continuation of the first, entitled "Must-Know Finance Concepts for Life Sciences Valuations." It goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets....

Four panelists from leading global pharmaceutical companies and research organizations discussed theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more. 

There are few people in the world like James Greenwood, BIO CEO, who have as much experience and expertise in successfully connecting biotech companies with large pharma. We recently had the opportunity to sit down with him and pick his brain about the future of biopharma partnering.

Using suppliers is an excellent way to get access to skills and technology that aren’t available internally. However, using suppliers may also create wasted time and effort on the part of the company and the supplier. After both working with suppliers and being a supplier, Maren Nelson has learned...

Although we have long known about the existence of microbes—the tiny bacteria, fungi and archaea that live all around us, on us, and in us—interest in how the microbiome might impact human therapeutics has become a hot topic in research only recently...

When entering due diligence, it's important to know what information to share and when to share it ensure a timely process. This excel-based due diligence checklist - which is easy to upload to a virtual data room - is designed to make sure you have the information you need for a streamlined due diligence process. 

Due diligence and finance experts from global pharmaceutical companies join legal advisors and consultants to share their expertise in a lively discussion on the issues that arise during due diligence.

 

Learn how Cure SMA leveraged a ShareVault virtual data room to advance one of the very first drug programs focused on finding a cure for Spinal Muscular Atrophy.